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Abstract: 
Cerebral small vessel disease (SVD) is a common accompaniment of ageing, whose visible neuroimaging features include recent small subcortical infarcts, lacunes, white matter hyperintensities, perivascular spaces, microbleeds and brain atrophy. SVD may present as a stroke or cognitive decline, or may be asymptomatic or minimally symptomatic, and frequently coexists with neurodegenerative disease where it may exacerbate cognitive deficits, physical disabilities, and other symptoms arising from neurodegeneration. The terminology and definitions used to describe imaging features of SVD vary widely as do protocols for image acquisition and image analysis. This lack of consistency obstructs progress in determining the contribution that SVD makes to the pathophysiology and clinical expression of common neurodegenerative diseases. Against this background, an International working group of the Centres of Excellence in Neurodegeneration completed a structured process to develop definitions and imaging standards for specific markers and consequences of SVD. The group was charged with the following tasks: to i) provide a common advisory terminology and definitions for imaging features of SVD visible on magnetic resonance (MR) imaging (MRI), ii) suggest minimum standards for their image acquisition and analysis, iii) agree on standards for scientific reporting of small-vessel-related changes on neuroimaging, iv) review emerging imaging methods for detecting and quantifying preclinical manifestations of SVD. Our findings apply to research studies and in addition can be used in the clinical setting to standardise image interpretation, acquisition, and reporting.
This manuscript summarises the main outcomes of this international effort to provide the STandards for ReportIng Vascular Changes on NEuroimaging (STRIVE). 

Funding: Centres of Excellence in Neurodegeneration (COEN) concordat (United Kingdom Medical Research Council, the German Center for Neurodegenerative Disease [Deutsches Zentrum für Neurodegenerative Erkrankungen, DZNE], Germany) and the Canadian Institutes of Health Research [CIHR, Canada]) reference COEN017; Royal Society of Edinburgh; Scottish Imaging Network, a Platform for Scientific Excellence (SINAPSE) Collaboration; UK Cross-Council Centre for Cognitive Ageing and Cognitive Epidemiology, Edinburgh; Carl Friedrich von Siemens Foundation; Vascular Dementia Research Foundation; NIHR Biomedical Research Unit in Dementia awarded to Cambridge University Hospitals NHS Trust and the University of Cambridge; NIHR Biomedical Research Unit in Dementia awarded to UCL Hospitals NHS Trust and UCL; 
FP6 ERA-NET NEURON grant (01 EW1207); and Canadian Stroke Network.


Introduction
Neurodegenerative diseases such as Alzheimer’s disease (AD) commonly co-exist with cerebrovascular disease in older people. Cerebral small vessel disease (SVD) is the commonest vascular cause of dementia, the major contributor to mixed dementia, and is the cause of at least a fifth of all strokes.1,2 AD and SVD share risk factors,3,4 both lead to cognitive decline and dementia,5-7 and the clinical differentiation of AD from “vascular cognitive impairment” or “vascular dementia” is recognised increasingly to be blurred.8 

Visible manifestations of SVD on conventional MR imaging (MRI) include recent small subcortical infarcts, white matter MR hyperintensities (WMH), lacunes, prominent perivascular spaces (PVS), cerebral microbleeds (CMB) and atrophy.2 However, the terms and definitions of these lesions have varied hugely across studies.9,10 For example, our systematic review of terms for WMH identified 1,144 instances of 50 different terms used to describe WMH among 940 publications; in some cases two different terms were used within the same publication (table 1 and appendix). This degree of variation in terms inhibits cross-study comparisons, and is a barrier to research on the risk factors, pathophysiology, pathological correlations and clinical consequences of these lesions. Indeed, the same lesions may be classified differently across studies—for example, small cavities have been variably classified as either perivascular spaces or lacunes by different definitions.9 Variable fates of acute SVD-related lesions and convergence of aetiologically different lesions into similar appearances on MRI (figure 1) adds to the difficulties in interpreting data from many research reports. More standard terminology, definitions, image acquisition and analysis methods across research centres would remove a major barrier to progress in the field. Furthermore, such standardization could be adopted in clinical practice to improve our ability to diagnose and understanding the cause of cognitive impairment in the elderly

Neuroimaging consensus standards for SVD classification were first proposed by the U.S. National Institute of Neurological Disorders and Stroke (NINDS) and Canadian Stroke Network (CSN) as part of standards for vascular cognitive impairment (VCI) research.11 Subsequently, a scientific statement from the American Heart Association incorporated neuroimaging evidence of SVD or stroke as part of “probable” criteria for vascular mild cognitive impairment and dementia, and included a class II recommendation for neuroimaging as part of the work-up for vascular cognitive impairment.12 However, neither of these guidelines provide comprehensive recommendations for the many neuroimaging manifestations of SVD, and neither reflect recent advances in understanding the pathophysiology and measurement of SVD, a rapidly changing field.

This international effort builds on prior initiatives to provide clear, scientifically rigorous, evidence based, easy to apply definitions and terminologies for structural neuroimaging features of SVD that avoid presuming mechanisms of pathogenesis, with examples to facilitate improved standard use; minimum advisory standards for image acquisition; standards for analysis of neuroimaging SVD and related features; and scientific reporting standards to improve clarity of publications on SVD. The present standard focuses on SVD. However other vascular lesions, including non-SVD-related ischemic or haemorrhagic stroke, subarachnoid haemorrhage, subdural hematoma and vascular malformations, can also contribute to cognitive impairment and dementia, especially after stroke. These, and neuroimaging recommendations, are discussed in the appendix.

This manuscript summarises the resulting STandards for ReportIng Vascular Changes on NEuroimaging (STRIVE). Our primary aim is to recommend standards for research using MRI; however, many of the principles also apply to research using CT, and the standards may also facilitate a more consistent approach to identifying neuroimaging manifestations of SVD in clinical practice.

Methods
In 2011, the United Kingdom Medical Research Council, the German Center for Neurodegenerative Disease (DZNE, Germany) and the Canadian Institutes of Health Research (CIHR, Canada) issued a call for proposals under a funding concordat the Centres of Excellence in Neurodegeneration (COEN) which aimed to accelerate progress in understanding the pathogenesis of neurodegeneration (www.coen.org).13 This provided funding for a working group of experts to establish standards for neuroimaging in SVD.

The core group of experts was convened in Edinburgh in March 2012. These experts were identified by three study co-chairs (JW, MD and EES) based on location in a COEN-affiliated Centre, supplemented by representatives from active research groups in SVD neuroimaging in non-COEN participant countries. The group included experts in neurology, neuroradiology, neuroepidemiology, psychiatry, geriatrics, stroke, medical imaging physics and neuropathology. The working method was based on the Delphi principle, with workshops at the beginning and end of the project and interim work packages (details in appendix). A template focused the discussion on achieving a consensus in key areas: terminology, definitions, image acquisition, image analysis, and reporting standards. The group endorsed a key principle that terms and definitions should reflect imaging characteristics as descriptively as possible, avoiding unfounded presumptions of mechanism or pathological correlation not well supported by the scientific literature, so as not to inhibit future studies of the pathophysiology of SVD. Subsequently, working groups were assigned to develop standards for each of six key lesion types, following established principles for guideline development published by the equator network (http://www.equator-network.org/ (​http:​/​​/​www.equator-network.org​/​​)). Systematic searches were conducted to identify relevant literature (appendix). The entire group reconvened in Munich in November 2012 to present draft standards from each working group for discussion and revision, with additional review and comment from six external advisors newly invited to the process. This consensus document was drafted and revised with input from all workshop members. The final manuscript document was reviewed and endorsed by all participants.

For each of six key SVD lesion types, we describe the context, terminology and definitions. Image acquisition, image analysis and reporting standards for SVD-related lesions are described thereafter. We also comment on haemorrhage as a component of SVD and other vascular lesions as these may contribute to dementia (appendix). We discussed size limits for perforating arteries and arterioles to determine the correct term, but found these to be highly variable in the literature and not well translated to their appearance on imaging. We therefore decided to use the term ‘arteriole’ to refer to small perforating arteries/arterioles that are affected in SVD. Example images of the key SVD lesion types are given in figure 2, with further details in the appendix. These standards are expected to reliably classify most neuroimaging manifestations of SVD; however, we acknowledge that individual investigator judgment may be required to classify ambiguous lesions on the borderline between clear cut categories (appendix), and that clinical judgment may be even more necessary when using these standards in clinical practice. 

Context, terminology and definitions of individual imaging features of SVD
Recent small subcortical infarcts 
Context: Clinically evident recent small subcortical infarcts (SSI), frequently referred to clinically as “lacunar stroke” or “lacunar syndrome”, cause about 25% of all ischaemic strokes (figure 2). Occasionally, a recent asymptomatic SSI may be identified serendipitously on imaging,14,15 and referred to as a ‘silent cerebral infarct’. Conversely, for as yet unexplained reasons, symptomatic lacunar stroke syndromes may not be accompanied by visible SSI in up to 30% of cases,16 indicating that MRI is not perfectly sensitive for recent SSI. Additionally, more recent work demonstrates that SSI may have variable fates, evolving into either a lacunar cavity, a T2 hyperintensity without apparent cavitation, or may disappear leaving little visible consequence on conventional MRI (figure 1). Estimates of the proportion of recent SSI that cavitate range from 28%17 to 94%.18 

Limited pathological correlation studies suggest that SSI may be associated with small artery occlusion, although the aetiopathogenesis of SSI is unclear. SSI occur in the perfusion territory of a small artery or arteriole penetrating into the internal part of the brain. MRI studies suggest that recent SSI may exceed 15 mm axial diameter (the usual size limit for lacunes of presumed vascular origin, see below) in the acute phase and can range up to approximately 20 mm on axial sections. MRI also shows that SSI and lacunes may exceed 20 mm in length when measured in the coronal or sagittal plane (appendix).

Terminology: A sampling of 641 abstracts and a prior systematic review9 identified 159 different terms for recent SSI; the commonest terms included lacunar infarcts, lacunar infarctions and lacunar strokes (appendix). We propose the new consensus term recent small subcortical infarct (rSSI), dropping the term “lacunar” because of emerging evidence that not all small subcortical infarcts become lacunes (i.e. cavities).17,18 

Definition: We propose that recent small subcortical infarct should refer to neuroimaging evidence of recent infarction in the territory of a single perforating arteriole with imaging features or correlating clinical symptoms consistent with a lesion occurring in the last few weeks (table 2). “Recent” should refer to lesions with symptoms or imaging features suggesting that they occurred within the last few weeks and is used instead of ‘acute’ to reflect the first few weeks not just the hyperacute stage. “Small” indicates a lesion that should generally be less than 20 mm maximum diameter in the axial plane, although it is acknowledged that some lesions that appear to represent infarction in the territory of a single vessel could be somewhat larger in the coronal plane (appendix).19 Additional research is required to determine the upper size limits more precisely. Lesions in the basal ganglia and internal capsule that are larger and appear to represent infarction in multiple penetrating arteries simultaneously should not be classified as SSI, rather as the aetiologically distinct subtype of infarction, striatocapsular infarct.20 Similarly, anterior choroidal artery infarcts are also aetiologically distinct, identifiable by their location (in the caudate nucleus head) and shape (usually ‘comma’ shaped) so should not be classified as SSI. There is no lower size limit for SSI, in contrast to lacunes of presumed vascular origin, because positive diffusion-weighted images (DWI) allow discrimination of small recent infarcts from perivascular spaces. MR signal characteristics of rSSI are given in figure 2. 

Lacunes of presumed vascular origin
Context: Miller Fisher wrote concerning pathology: “Historically, the original small vessel disease feature was the ’lacune‘ (hole) which derived from French for a small fluid-filled cavity that was thought to mark the healed stage of a small deep brain infarct. The term was adopted into English. By a process of medico-linguistic evolution, the precavitary phase became the lacunar infarct, the associated clinical entity became the lacunar stroke and the neurological features became the lacunar syndrome”.21 Lacunes are commonly seen on imaging in asymptomatic elderly and are associated with an increased risk of stroke, gait impairment and dementia.22-25 Most lacunes are presumed to result from SSI, symptomatic or silent; however, some may represent the sequelae of small deep haemorrhages (figure 1).26 

Terminology: A systematic review identified more than 100 terms that have been used to describe lacunes of presumed vascular origin (appendix); commonly used terms included “lacune”, “lacunar stroke” and “silent brain infarct”. We propose the new term lacune of presumed vascular origin, which discriminates small cavitated lesions of presumed vascular origin from other small brain cavities, and accommodates the fact that there may be some uncertainty regarding ischemic or hemorrhagic origin of the lesion when imaging in the acute phase is unavailable, as is commonly the case.

Definitions: We define a lacune of presumed vascular origin as a round or ovoid, subcortical, fluid filled (similar signal to CSF) cavity between 3 and about 15 mm in diameter, compatible with a previous acute small deep brain infarct or haemorrhage in the territory of a single perforating arteriole (table 2). MRI signal characteristics are given in figure 2. On fluid-attenuated inversion recovery (FLAIR) images, lacunes of presumed vascular origin usually have central CSF-like hypointensity with a surrounding rim of hyperintensity although the rim is not universal and a hyperintense rim may also surround PVS when passing through a WMH. In some cases the central cavity fluid may not be suppressed on FLAIR, such that the lesion appears entirely hyperintense on FLAIR despite clearly showing CSF-like intensity on other sequences such as T1-weighted (T1-w) and T2-weighted (T2-w).18 Lacunes of presumed vascular origin should be distinguished from perivascular spaces (PVS). Although pathological studies show that there is no absolute size cut-off, lesions <3 mm in diameter are more likely to be PVS than lacunes (appendix) and therefore we recommend the continued use of this size criterion to discriminate the two lesion types, consistent with prior studies.27,28 The maximum size of 15 mm was chosen to reflect the generally smaller size of old versus recent infarcts due to tissue loss and ex-vacuo effect in the former and swelling in the latter, but we recognise that there is little objective data to support this size boundary and that more research is required. 

White matter hyperintensities of presumed vascular origin 
Context: White matter lesions marked by usually  bilateral and largely symmetrical hyperintensities on T2-w images are common in older subjects. They are strongly associated with cerebrovascular disease and vascular risk factors,29 although their pathogenesis is poorly understood and may be multifactorial.30 WMH are associated with covert neurological and cognitive symptoms and physical difficulties such as gait disturbance.31-35 Hyperintensities may be present in subcortical gray matter structures, such as the basal ganglia as well, and have sometimes been analyzed together with WMH. They may also be present in the brainstem. Some studies have distinguished between perivascular and deep WMH (appendix) in analysis, with the suggestion, as yet the subject of debate, that they may have different pathogenesis, risk factors and clinical consequences. Many studies analyze total WMH. 

Terminology: A systematic review of 940 abstracts identified 50 different terms for WMH; the commonest terms were leukoaraiosis, white matter lesions, white matter hyperintensities, leukoencephalopathy (usually in the context of CADASIL) and white matter disease (table 1; appendix). Leukoaraiosis is a descriptive term for reduced x-ray attenuation seen on CT,36 subsequently adopted to denote hyperintensity on T2-w and FLAIR, sometimes also hypointensity on T1-w MR images (appendix), reflecting a situation in which radiological preceded pathological description. We propose the term white matter hyperintensity of presumed vascular origin (WMH) to exclude white matter lesions from other diseases such as multiple sclerosis or leukodystrophies. 

Definitions: MRI signal characteristics of white matter hyperintensities of presumed vascular origin (WMH) are provided in figure 2. On T1-w sequences WMH may appear iso- or hypointense depending on the sequence (and severity of pathology), although the hypointensity should not approach that of CSF (table 2; appendix). Opinion was divided regarding whether gray matter hyperintensities or brainstem hyperintensities should be classified routinely as “WMH”, as some studies have done. The consensus opinion was that lesions in the subcortical gray matter or brainstem are not included into the WMH category unless explicitly stated; the use of the term “subcortical hyperintensities” was endorsed as an acceptable alternative collective term to refer to any non-cortical hyperintensities including those in white matter, deep gray matter and brainstem. In the context of CT scanning, the term ‘white matter hypoattenuation’ or ‘white matter hypodensities’ can be substituted, reflecting their appearance on CT

Perivascular spaces
Context: Perivascular spaces (PVS) constitute an extension of the extracerebral fluid spaces around arteries, arterioles, veins and venules as they course from the brain surface into and through the brain parenchyma and are variably followed by sheets of leptomeninges (figure 2).37 PVS are most often microscopic and thus not visible by conventional neuroimaging, but larger ones tend to become increasingly apparent with increasing age especially at the base of the brain.38 A more general enlargement of PVS has been associated with other morphologic features of small vessel disease such as white matter hyperintensities39 and lacunes,40 but not atrophy.41 The clinical significance of having numerous visible PVS is still controversial and they should therefore not be termed “lesions”; however, emerging evidence associates more prominent PVS with worse cognitive function.42 

Terminology: Synonymous terms for PVS include “Virchow-Robin Space” (VRS),40 “type 3 lacune”,43 or (when predominantly in the basal ganglia) état crible.38 Numerous terms such as large’, ‘dilated’, ‘large dilated’ or ‘enlarged’ ‘VRS’ or ‘PVS' have also been used to describe visible PVS.38,41,42,44-48 These were not considered appropriate because the relationship between PVS size and clinical consequences is not well understood, and because the visibility of PVS depends on MR sequence characteristics which vary across studies, therefore visibility alone cannot be a uniform criterion for pathologically enlarged PVS. We therefore recommend the consensus term perivascular space (PVS). 

Definitions: Perivascular spaces (PVS) are defined as fluid-filled spaces, which follow the typical course of a vessel penetrating/traversing the brain through gray or white matter; with signal intensity similar to CSF on all sequences (figure 2); because they follow the course of penetrating vessels, they will appear linear when imaged parallel to the course of the vessel and round or sometimes ovoid shape with a diameter commonly not exceeding 2 mm when imaged perpendicular to the course of the vessel (table 2; appendix). At high resolution, a central vessel may occasionally be seen coursing through the centre of the PVS, possibly differentiating them from lacunes. PVS tend to be most prominent in the inferior basal ganglia, may also be seen coursing centripetally through the hemispheric white matter and in the midbrain, but are rarely if ever seen in the cerebellum. They may exhibit focal enlargement, and can be particularly enlarged (up to 10-20 mm even with mass effect) in the inferior basal ganglia. PVS must be discriminated from small lacunes of presumed vascular origin (appendix). In contrast to lacunes, PVS usually do not exceed a diameter of 2 mm as confirmed pathologically,49,50 and do not have a T2 hyperintense rim around the fluid filled space on T2w or FLAIR imaging, unless they happen to be coursing through an area of WMH.51 

Cerebral Microbleeds
Context: Microbleeds are small hypointense lesions on paramagnetic sensitive MR sequences such as T2*-weighted gradient-recalled echo (GRE) or susceptibility-weighted sequences, and are most frequently located in the cortico-subcortical junction, deep grey or white matter in the cerebral hemispheres, brainstem and cerebellum (figure 2). Pathologically, the few correlative studies30,52,53 suggest that the MR-visible lesions correspond to haemosiderin-laden macrophages in perivascular tissue consistent with vascular leakage of blood cells.52,54-56 Cerebral microbleeds are associated with SVD and Alzheimer’s disease.57,58 The presence or absence of strictly lobar microbleeds has been incorporated into research criteria for cerebral amyloid angiopathy (CAA).59 Originally thought to be asymptomatic markers of SVD, emerging studies demonstrate associations with cognitive impairment although the mechanisms of the association, including whether microbleeds directly damage the brain and cause dysfunction, are not well understood. Recommendations for microbleed imaging and reporting have been recently published, and we endorse the use of these standards.60 When microbleeds occur in the context of AD or beta-amyloid immunotherapies they have been termed amyloid-related imaging abnormalities-haemorrhage (ARIA-H). A consensus group convened by the Alzheimer’s Association has recently published standards for assessing microbleeds in this specific clinical context,61 and we endorse the use of these guidelines as well. 

Terminology: A literature search revealed 387 instances of 20 different terms for microbleeds in 370 abstracts (appendix). Microbleed was by far the commonest term, followed by ‘cerebral microbleed’ and then ‘brain microbleed’. We propose the consensus term cerebral microbleed.

Definitions: Cerebral microbleeds (CMB) are visualised as small (usually 2-5 mm or sometimes 10 mm in diameter) areas of signal void with associated “blooming” on T2* or other MR sequences sensitive to susceptibility effects,57,60 (table 2) that are generally not visualised on CT or on FLAIR, T1-w- or T2-w MR sequences. On T2*-weighted (T2*-w) gradient-recalled echo (GRE) images, they are well defined, of homogeneous low signal, either round or oval, in shape (figure 2). Because the blooming artifact, and therefore the visualized size, depends on MR field strength and sequence we do not recommend an absolute criteria for size. On 1.5 and 3T GRE, CMB are usually 2-5 mm, but can range up to 10 mm in diameter. Hypointensities less than 2 mm, which could represent signal loss over only a single voxel, should be regarded as questionable on MRI at 1.5T because such small hypointensities could be artifactual. Susceptibility-weighted imaging (SWI) may also be used to assess CMBs. Emerging quantitative based methodologies (i.e., quantitative susceptibility mapping, QSM) require more evaluation, but may provide improved methods for CMB assessment. Several lesions or structures may mimic cerebral microbleeds and should be considered, including calcification, normal vessels seen in cross-section, iron deposits from other causes, haemorrhagic metastases (e.g. melanoma), and diffuse axonal injury (e.g. after head trauma).60 CMB may be differentiated from old small deep spontaneous intracerebral haemorrhage because, in general, the latter may be larger, irregular with a cystic cavity (figure 1), and will be usually be visualised on T1-w, and T2-w or FLAIR imaging. 

Other haemorrhagic lesions
The consensus group discussed two other haemorrhagic manifestations of SVD worthy of mention: intracerebral haemorrhage and superficial cortical siderosis (appendix).

Intracerebral haemorrhage (ICH) may be a manifestation of SVD62 or may be secondary to other causes such as vascular malformations. The consensus term spontaneous ICH presumed due to SVD was suggested, as opposed to secondary ICH from other causes or traumatic ICH. Comprehensive guidelines for the diagnosis and management of ICH have been published previously. In the context of studying SVD, we promote research to disentangle the contribution of different vascular diseases to ICH; in the meantime, we recommend that lobar ICHs, which may be caused by CAA, should be distinguished from non-lobar ICHs, which are thought generally not to be caused by CAA and are mostly attributed to perforating arteriolar vasculopathy.63,64 A small study suggested good, but not perfect, inter-rater agreement on the site of origin of ICH.65 The Boston criteria for CAA should be considered for use in assigning the likelihood of underlying CAA in patients with lobar ICH.59

We propose the consensus term superficial cortical siderosis to refer to neuroimaging evidence of chronic blood products in the superficial cortex just below the pia. Superficial cortical siderosis may be a chronic consequence of subarachnoid bleeding or may result from other causes of very superficial cortical bleeding, including vascular malformations, CAA,66 spinal dural defects, or may be idiopathic.66,67 It is visible as linear hypointensity overlying the cortex on T2* GRE or other blood-sensitive sequences. It may be mimicked by petechial cortical haemorrhagic transformation of an infarct. Revised research criteria for CAA incorporate the presence of superficial cortical siderosis as another haemorrhagic manifestation of CAA, equivalent to a lobar ICH.66 The location of the siderosis (the number of sulci involved66 and in which lobes) should be described.

Brain Atrophy
Context: Brain atrophy can be generalized or focal (affecting only particular lobes or specific brain regions, e.g. the hippocampus), symmetrical or asymmetrical or tissue selective (affecting a certain tissue class, e.g. white matter) and occurs in many conditions. The pathological changes that underlie atrophy are heterogeneous and do not necessarily reflect neuronal loss.68-70 Brain atrophy accompanies normal ageing to a varying extent. In the context of vascular disease and dementia, the neuropathological substrate of atrophy includes neuronal loss,71 cortical thinning, subcortical vascular pathology with white matter rarefaction and shrinkage, arteriolosclerosis, venous collagenosis and secondary neurodegenerative changes.72,73 Many imaging studies have observed an association between presence and severity of SVD and brain atrophy, including global atrophy as well as atrophy of the corpus callosum, central atrophy (with increased ventricular size and atrophy of the basal ganglia), mesencephalic atrophy, hippocampal atrophy, and focal cortical thinning in brain regions connected to subcortical infarcts (figure 3).74,75 Vascular lesions should therefore be considered in studies that focus on atrophy and conversely, atrophy is an important measure in imaging studies that assess the burden of vascular damage in the brain and mediates at least partially the effects of vascular lesions on cognition.76-78

Terminology: A systematic review of literature on SVD and atrophy revealed use of multiple synonymous terms including “atrophy”, “brain volume”, “volume loss” and others. We propose the consensus term brain atrophy. We also propose that studies should use unambiguous terms regarding whether the atrophy assessment was cross-sectional or longitudinal, and avoid the use of terms such as “accelerated atrophy” or “brain volume loss” in cross-sectional studies, in favour of “more atrophy” or “lower brain volume”. When discussing atrophy, investigators should be clear regarding which brain volumes have been measured and should consider including the brain subregion in their description- e.g. hippocampal atrophy.

Definitions (table 2): We define ‘brain atrophy’ in the context of SVD, operationalised through imaging, as lower brain volume, not related to a specific macroscopic focal injury such as trauma or infarction. Tissue loss is often inferred from enlargement of peripheral (sulcal) and central (ventricular) cerebrospinal fluid (CSF) spaces in relation to the intracranial volume and other measures (figure 3). However, in the strict sense such assumption would require longitudinal observation. Tissue loss resulting from discrete focal lesions, such as cortical infarcts, is more easy to substantiate cross-sectionally and should not be confused with generalised global or regional brain atrophy likely secondary to a diffuse process. 

Other vascular lesions
These consensus standards are focused on SVD. However, there are other vascular lesions that may be seen particularly in the elderly subjects and in subjects with cognitive impairment. They include non-SVD-related ischemic stroke, ICH from non-SVD causes, subarachnoid haemorrhage, subdural hematoma, vascular malformations and larger arterial ischaemic disease. These are described in detail in the online appendix.

Advisory minimum standards for imaging of SVD 
Image acquisition standards and parameters (table 3)
For both routine clinical and research uses, if there are no contraindications then MR is preferred to CT as MR has higher sensitivity and specificity for detecting most manifestations of SVD. Field strength of 3T may be preferred, but modern 1.5T is often of as high definition,79 is acceptable and may be more widely available, an important consideration for multicenter studies. Regardless, imaging sequences should be optimized for field strength and scanner configuration. If CT is used in SVD, then a thin section volume sequence without contrast covering the whole brain on a brain parenchymal algorithm and axial 5 mm reconstructions should be obtained. However, in general, CT is no longer recommended except possibly in large scale epidemiological studies or where MR imaging is not available or too expensive.

For MR imaging, the minimum acceptable MR examination should include axial DWI (and ADC map), FLAIR, T2-w, GRE/T2*-w or SWI, and T1-w images. The DWI sequence is vital for identifying recent infarcts, e.g. in symptomatic patients. MRI with DWI should be considered the reference standard for recent SSI, although it may be negative in some cases.16 Clinical syndrome plus MR without DWI, or clinical syndrome plus CT, is suboptimal, and clinical syndrome alone is least reliable.80 Acquiring one of these sequences (T1-w usually) in the coronal or sagittal plane instead of axial facilitates visualisation of the true lesion dimensions (appendix). Slice thickness should be 5 mm or less, ideally with no gap; in-plane resolution should be 1 mm by 1 mm or better. Whole-brain coverage is recommended for all sequences for optimum image analysis. A 3D T1-w thin section isotropic sequence is now commonly available, quick and can be reformatted on thicker slices for ease of viewing in multiple planes: this sequence also allows anatomical co-registration and quantification of brain volume. 3D MT T1-w sequence protocols for the major scanner types at 1.5 and 3T have been validated in the Alzheimer’s Disease Neuroimaging Initiative (ADNI); sequence protocols are freely available on the web (www.adni-info.org).

A comprehensive SVD-intensive research MR protocol should consider acquiring the MR data at higher resolution than the sequences specified above, using volume acquisitions to allow for volumetric whole brain imaging with near- isotropic resolution. These 3D acquisitions are now possible on most scanners for T1-w, T2-w, T2* GRE, SWI and/or FLAIR techniques. Alternative high resolution sequences sensitive to paramagnetic content such as SWI and equivalents should be considered, although these also generate more artefacts. Diffusion tensor imaging (DTI) extends DWI and should be used in research protocols. DTI is useful for assessing surrogates of microarchitectual integrity of normal-appearing and lesional white matter, to determine structural connectivity of white matter and in tractography. For quantitative volumetric assessments of atrophy, a high resolution (1 to 1.5 mm isotropic voxels) T1w sequence with good gray-white matter differentiation is advised. Other MR measurements show great promise for SVD in research applications including measurements of perfusion, magnetisation transfer, blood-brain barrier permeability, vascular reactivity, metabolites, and microatheroma in perforating arterioles (see Future Directions).

Image analysis standards (table 4; appendix)
For all lesion types, qualitative (visual rating) and quantitative (computational analysis) methods are established or emerging. For at least some lesion types, these two approaches are highly correlated;81,82 both have advantages and disadvantages that should be considered in the design of any SVD study. Full details of image processing are given in the appendix.

For all lesion types, observers should be trained in brain imaging interpretation and specifically how to recognize SVD lesions. If possible, particularly in trials or large observational studies, images should be rated centrally by a single or small number of experienced raters. If more than one rater is used, inter-rater reliability should be assessed. To measure global and regional atrophy, observers should have good knowledge of normal neuroanatomy. Observers should train on established training sets and should aim for high observer agreement before undertaking actual measurements. Regular ‘recalibration’ against standard examples is useful to maintain consistency when rating large numbers of scans or when rating scans in different sessions. 

When using automated computational methods for analysis, we emphasize that the accuracy of each subject’s output should be visually confirmed by a trained observer. This validation step is critical for studies of SVD because many automated methods have not been developed for SVD specifically and there is a high risk of misclassification of SVD lesions as other lesions or tissue classes, especially when unfamiliar pulse-sequences are used or scanners are upgraded. Known examples to avoid include misclassification of WMH as normal gray matter, of lacunes as ventricle or WMH, or of SSI as WMH.83 Several of these misclassifications will require manual correction.77,84

For small discrete lesions of limited number, such as rSSI, lacunes, and microbleeds, we recommend recording the location of each lesion and the total number of lesions. At minimum, we recommend recording the number of lesions in each of the following brain subregions, on the right and left side: cerebral cortex (divided by lobe), corona radiata/centrum semiovale, putamen, globus pallidus, thalamus, internal capsule, external capsule, brainstem, and cerebellum. Detailed recommendations for analysis of different lesion types are summarized in table 4 and in the appendix.

Reporting standards for vascular findings on neuroimaging (table 5)
Conduct and reporting of vascular findings on neuroimaging should follow standards already established for observational, epidemiological, diagnostic test assessment or randomised clinical trials (www.equator-network.org). In addition to these, we suggest some specific points that will aid progress in and standardize future research using imaging (table 5). We encourage future reports to use the terms and definitions for SVD-related imaging findings proposed above. Wherever possible studies using visual rating scales should employ established broadly used rating scales to secure comparability of studies and facilitate meta-analyses.

Future Developments and Challenges (table 6)
Advances in imaging technologies as well as novel protocols for image acquisition and image post-processing have improved options for imaging the various manifestations of SVD, with the potential to better clarify their role in neurodegenerative disease and to identify new mechanisms of disease. Examples include advances in small arterial imaging using ultra high-field strength MRI (>3T), DTI measures of detailed structural connectivity, magnetization transfer imaging assessment of white matter myelination, imaging of blood-brain barrier permeability and of vascular reactivity, perfusion imaging, imaging of retinal vessels, QSM and others. The advantages of multi-modal imaging should be exploited for advancing understanding of pathophysiology. For example, combining DTI and atrophy measures allows the study of the effects of vascular lesions on distantly connected brain regions.85

Importantly, there is increasing interest in the clinical relevance of further small brain infarct subtype, microinfarcts, which are very small ischaemic lesions found mostly in the cortex at autopsy in older people and visible in occasional subjects on high field MRI.86,87 Their true vascular pathological relationship to SVD is yet to be determined. Although yet to be confirmed, it is possible that some tiny cortical DWI acute lesions are microinfarcts.86 Microinfarcts appear to be highly clinically relevant, so neuroimaging methods to measure microinfarcts or a validated close surrogate is required. Larger cortical microinfarcts have been visualized on 7T MRI, which were sometimes visible on conventional 3T MRI as well.88

Comprehensive studies are now required that account for both vascular and neurodegenerative pathologies in patients followed over longer time periods from younger ages. These studies should include (amongst others) multimodal MRI, amyloid imaging with positron emission tomography (PET), detailed clinical testing, and biomarkers from serum and CSF to allow disentangling of the crosstalk between vascular and neurodegenerative pathologies and how these interact to cause clinical symptoms in particular cognitive decline, gait impairment, physical disability and depression. There is considerable need for more imaging-pathology correlation.30,52 Additionally, carefully conducted imaging studies with repeat short-term (e.g. monthly) follow-up are required to study the progression of SVD-related imaging features and their impact on brain tissue loss. 

Conclusions
These neuroimaging standards for SVD are intended to harmonize current disparate terminology and analysis methods. We encourage other researchers to adopt these standards. They may serve as a useful introduction to the principles of SVD neuroimaging, that may assist investigators seeking to incorporate measurement of SVD into their own studies focused on neurodegenerative diseases or, even more broadly, the pathological basis of ageing. These standards should facilitate across-study comparisons of findings, accelerating translation of new findings into practice. Additionally, standardised approaches could enable formal between-study meta-analyses, which are increasingly required to obtain the sample sizes needed for some types of research such as genetic association studies. We suggest that our reporting standards may prove a useful guide to authors, peer reviewers and editors, and may elevate the methodological quality of neuroimaging studies of SVD just as analogous reporting standards (e.g. the CONSORT guidelines) have elevated the quality of other types of research. Finally, although the primary purpose of our standards was for research we hope that these standards will positively influence clinical diagnosis and the reporting of SVD lesions in routine clinical practice.

These standards were developed based on consensus among a relatively large group of experts using rigorous methods. However, we acknowledge that in some aspects of this rapidly evolving field, our recommendations are based on small studies, unvalidated findings or expert opinion without a strong body of supporting evidence. It is clear that future work is essential to validate these standards. In particular, the dearth of radiological-pathological correlation studies is a key limitation to our understanding of the neuroimaging of SVD. Additionally, it was recognized that best standards for SVD neuroimaging will change over time and therefore periodic revision of these standards will be required.
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Table 1: Terms used previously to describe white matter hyperintensities of presumed vascular origin

Term	Variants of use of term	Use of termin titles and abstracts
		Total No.*	%
leukoaraiosis	ischemic leukoaraiosis, subcortical leukoaraiosis	350	31
white matter lesions	MRI white matter lesions (WML), cerebral WML, T2 WML/WMLs, cerebrovascular WML, subcortical WML, WML of Binswanger's disease, cerebral WML of Binswanger's disease, confluent WML, intracranial WML	275	24
white matter hyperintensity	cerebral WMH, age-related WMH, brain WMH, MRI WMH	217	19
white matter changes	age-related cerebral white matter changes (WMC); age-related WMC, cerebral WMC, changes in white matter, age-related changes in WM	136	12
leukoencephalopathy	subcortical ischemic leukoencephalopathy	76	7
white matter disease	age-related white matter disease (WMD), cerebral WMD, subcortical WMD	45	4
white matter damage	age-related WMD, 	5	0
ischemic/ ischaemic white matter disease	ischemic subcortical WMD, chronic ischemic cerebral WMD, subcortical ischemic WMD	4	0
other terms (N=9)		17	1
Data were derived from structured literature search; for methodology see Supplemental material
*Number of instances term was mentioned at least once in the abstract or in the title. The total number of instances was N=1144



Table 2: Glossary of proposed terms and definitions for neuroimaging features of SVD

Proposed term	Definition 
Recent small subcortical infarct	neuroimaging evidence of infarction in the territory of a single perforating arteriole with imaging features or correlating clinical symptoms consistent with a lesion occurring in the last few weeks
Lacuneof presumed vascular origin	round or ovoid, subcortical, fluid filled (similar signal to CSF) cavity between 3 mm and 15 mm in diameter, compatible with a previous acute small small subcortical infarct or haemorrhage in the territory of a single perforating arteriole
White matter hyperintensityof presumed vascular origin	signal abnormality of variable size in the white matter showing the following characteristics: hyperintense on T2-weighted images like FLAIR without cavitation (signal different from CSF). Lesions in the subcortical gray matter or brain stem are not included into this category unless explicitly stated – where deep grey matter and brainstem hyperintensities are included as well, the collective name should be “subcortical hyperintensities”
Perivascular space	fluid filled space, which follows the typical course of a vessel penetrating / traversing the brain through gray or white matter; has signal intensity similar to CSF on all sequences; has a round or ovoid shape with a diameter commonly not exceeding 2 mm when imaged perpendicular to the course of the vessel
Cerebral microbleed	small (usually 2 mm – 5 mm or sometimes 10 mm in size) areas of signal void with associated “blooming” on T2* or other MR sequences sensitive to susceptibility effects
Brain atrophy	brain volume loss, not related to a specific macroscopic focal injury such as trauma or infarction . Thus, the latter is not included in this measure unless explicitly stated



Table 3: Proposed image acquisition standards for neuroimaging features of SVD

Sequence	Purpose*	Orientation	Target slice thickness/ in-plane resolution	Comment
Minimum essential sequences, e.g. for clinical or large scale epidemiological studies, generally available on most MR scanners
T1-weighted	important for discriminating lacunes from dilated PVS; for discriminating gray from white matter and for studying brain atrophy 	2D axial, sagittal, or coronal	3-5 mm/1 mm x 1 mm 	at least one sequence acquired in sagittal or coronal plane is helpful in visualizing full extent and orientation of lesions
Diffusion-weighted imaging (DWI)	most sensitive sequences for acute ischaemic lesions; positive up to several weeks after event	2D axial	3-5 mm/2 mm x 2 mm	reduced signal on apparent diffusion co-efficient map helps identifying recent from old lesions
T2-weighted	Brain structure; differentiate lacunes from WMH and PVS; identify old infarcts	2D axial	3-5mm/1 mm x 1 mm	
Fluid Attenuated Inversion Recovery (FLAIR)	identify WMH and established cortical or large subcortical infarcts; differentiate WML from PVS and lacunes	2D axial	3-5 mm/1 mm x 1 mm	
T2*-weighted gradient echo recalled (T2*-w GRE)	detect haemorrhage, cerebral microbleeds, siderosis; measurement of intracranial volume	2D axial	3-5 mm/1 mm x 1 mm	only reliable routine sequence for detection of haemorrhage
Other commonly available routine sequences, generally available on most MR scanners
Proton Density-weighted	detect WMH, infarcts, perivascular spaces(with T2w dual echo),other pathologies 	2D axial	3-5 mm/2 mm x 2 mm	now largely replaced by FLAIR
Magnetic resonance angiography (MRA)	ICA, vertebral, basilar or MCA/ACA/PCA stenosis or other pathology	post contrast or 3D time of flight for intracranial	3D, axial, coronal, sagittal reconstruction; 1 mm isotropic voxels	only large vessels visible at 1.5 or 3T; see below for perforating arterioles.
Sequences often available on commercial clinical MR scanners; used more for research studies at present but some techniques have rapidly emerging use in clinical protocols
Diffusion tensor imaging (DTI) with 6 gradient direction diffusion encoding 	diagnose recent infarct; allows measurement of mean diffusivity and fractional anisotropy	2D axial	3-5 mm2 mm x 2 mm	more detailed characterisation than DWI; acquisition time doubled
Susceptibility-weighted imaging (SWI) or equivalent	very sensitive to haemosiderin, measurement of intracranial volume	2D or 3D axial	2D: 3-5 mm/2 mm x 2 mm3D: 1 mm isotropic voxels	visualises more CMBs than T2* GRE imaging and more sensitive to artifacts including motion.
Research only sequences (i.e. require research expertise)
Isotropic volumetric T2-w	display fine detail of PVS	3D axial	1 mm isotropic voxels	allows post-acquisition reformatting, potentially could replace 2D T2-w imaging if signal-to-noise is judged adequate.
Isotropic volumetric 3D T1-w (eg using MP-RAGE)	Improved volumetric brain measurements – global and regional	3D axial	1 mm isotropic voxels	allows post-acquisition reformatting, potentially could replace 2D T1-w imaging if signal-to-noise is judged adequate 
Isotropic volumetric FLAIR	identification of WMH; cortical or subcortical infarcts	3D axial	1 mm isotropic voxels	allows post-acquisition reformatting, potentially could replace 2D FLAIR imaging if signal-to-noise is judged adequate; more homogeneous CSF suppression
Advanced DTI with >6 direction diffusion encoding (e.g. 32 or more diffusion encoding directions)	provides refined/superior quantitative measure of microscopic tissue changes 	2D axial	3-5 mm/2 mm x 2 mm	allows for tractography, connectome, and more accurate measure of mean diffusivity and fractional anisotropy
Magnetisation Transfer Ratio (MTR)	sensitive to demyelination and axonal loss	2D axial	3-5 mm/1 mm x 1 mm	requires experience in acquisition and interpretation; two measurements (with and without MT-pulse)
T1 mapping	determine water content of tissue	axial	3-5 mm/2 mm x 2 mm	requires experience in acquisition and interpretation;
Permeability imaging	estimate permeability of the blood-brain barrier	axial; sequential pre- and post-contrast	3-5 mm/2 mm x 2 mm	requires intravenous contrast injection; complex image processing; methods improving rapidly at present
Arterial spin labeling (ASL) perfusion imaging	measure tissue perfusion – quantitative, with assumptions	2D axial	3-5 mm/2 mm x 2 mm	complex to set up and run accurately; requires post processing; optimum processing strategies not yet confirmed; does not require contrast injection. 
Perfusion imaging (dynamic contrast enhancement, DCE, or dynamic susceptibility contrast, DSC)	provides semi-quantitative measures of blood perfusion in tissue perfusion 	2D axial	3-5 mm/2 mm x 2 mm	requires intravenous injection of contrast agent and post processing; optimum acquisition and/or processing not yet confirmed for T1 (dynamic contrast enhancement, DCE) or T2* (dynamic susceptibility contrast, DSC) approaches
functional MRI (fMRI)	measure brain function in response to task or stimulus or at rest of default mode networks	2D axial	3-5 mm/2 mm x 2 mm	complex set up, acquisition and processing 
Quantitative susceptibility mapping (QSM)	provides quantitation of susceptibility changes independent of scanner or acquisition parameters	2D or 3D axial	2D: 3 mm – 5 mm/
2 mm x 2 mmor3D: 1 mm isotropic voxels	uses an SWI-like acquisition but requires very complex post-processing methodology required; post processing strategies currently under investigation
Micro-atheroma- / arteriolar imaging	for visualizing perforating arteriolar anatomy and atheroma	uncertain, emerging method	uncertain, emerging method	promising experimental approach that requires >3 T scanner
*Note that MR at 3 Tesla (T) is preferred to 1.5T; although these standards are listed as minimum essential through to research only applications, these categories are not absolute, the purposes are variable, and will vary with investigator interest, expertise and available technology. 
2D: two-dimensional, 3D: three-dimensional; ACA = anterior cerebral artery, CMB = cerebral microbleeds, ICA = internal carotid artery, MCA = middle cerebral artery, MP-RAGE = magnetization-prepared rapid acquisition with gradient echo, PCA = posterior cerebral artery, PVS = perivascular spaces, WMH = white matter hyperintensities.



Table 4: Proposed analysis standards for neuroimaging features of SVD

Measures of interest	Qualitative	Quantitative	Study design	Accuracy, reliability,feasibility	Generalcomment
Recent small subcortical infarcts
number (multiplicity may indicate causes other than SVD)89,90size (max. diameter)volumelocation (anatomical region; vascular territory)shape (round, ovoid, tubular)swelling (indicates recent not old)	various coding schemes available for location:anatomical: e.g. centrum semiovale, corona radiata, basal ganglia, thalamus, internal capsule, external capsule, optic radiation, cerebellum, brain stemvascular territory: e.g. middle cerebral artery, posterior cerebral artery, internal carotid artery, basilar artery	possible but impractical for size and volume	cross-sectional and longitudinal: recent small subcortical infarcts are typically detected in the setting of an acute clinical event but may also be an incidental finding	easy to identify on DWI, reliability depends on time between infarct occurrence and imagingmore difficult on other sequences or on CT without longitudinal data	mimics include acute inflammatory MS plaques acute lesions usually have increased signal on DWI and reduced signal on apparent diffusion coefficient images
Lacune of presumed vascular origin
number (single or multiple)size (max. diameter)shape (round, ovoid, tubular, other)location (anatomical region)evidence of previous hemorrhageex vacuo effect	various coding schemes available for shape and for location: anatomical: e.g. lentiform nucleus, thalamus, internal capsule, centrum semiovale, brain stemprominent ex-vacuo effect indicates lesion was originally larger (e.g. striatocapsular infarct)20	protocols for quantitative measurements available, require manual correction	cross-sectional and longitudinal: particular care is required to differentiate lacunes from PVSlongitudinal:difference imaging helps identifying incident lacunes	differentiation from PVS may be difficultaim for high observer agreement before undertaking actual ratings	hypointense rim on T2* suggests previous small deep haemorrhage
White matter hyperintensities
volumelocation (anatomical region) number	various coding schemes available for location:anatomical: e.g. perivascular, deep, subcortical, brain stem; or centrum semiovale, corona radiata, internal capsule, external capsule, optic radiation, brain stem; or frontal, temporal, parietal, occipital	various visual rating scores91-96 and protocols for quantitative measurements84,97-100 available, the two approaches are complementary81,82outputs should be visually reviewed by an experienced rater for mimics, artifacts, focal infarcts and mislabeling	cross-sectional and longitudinal: consider masking recent small subcortical lesions, lacunes, and PVS when measuring WMH volume to avoid inflating WMH volumeslongitudinal:difference imaging may help identifying new white matter lesions	inter and Intra-rater reliability for both qualitative and quantitative analysis of WMH quite high if performed by trained raters, with ICCs generally above 0.90visual rating scores may have ceiling or floor effects, so performance may differ with more or less disease	careful visual checking at all stages of computational analysis required to avoid problems from excess lesion distortion by e g bias field correctionconsider regular ‘recalibration’ against standard examples when rating large numbers of scans
Perivascular spaces
number (multiplicity) location (anatomical region)size (max. diameter)shape (see text)	anatomical: midbrain, hippocampus, basal ganglia, centrum semiovale	visual scores rate number of lesions in basal ganglia, centrum semiovale, midbrain etc.42,45,46various threshold-based methods are in development 	cross-sectional: consider masking PVS when measuring WMH volume, although this may be difficultlongitudinal:little experience	difficult to determine, especially when numerous and in the presence of WMH 	can be difficult to distinguish from lacunesgiant PVS may reach size >2cm, most commonly located below putamen
Cerebral microbleeds
number (few or multiple)location (lobar, deep, or infratentorial; anatomical region)size	semi-automated approaches, which segment cerebral microbleeds as an extra tissue class or radial symmetry and mask out areas of mineralization are being described101,102 but are experimental at the present time and require validation	several visual scores available60,60,103,103,104,104currently, there are no methods for automated detection	cross-sectional and longitudinal: consider using visual scores longitudinal:no specific scores for longitudinal studies 	there is some variability in inter-rater agreement on presence/absence of one or two microbleeds, but reasonable agreement (i.e. 0.8) between the numbers of microbleeds, reliability can be improved through the use of standardized scales60,103,104	lobar and deep cerebral microbleeds may have different risk factors and causes (e.g. lobar cerebral microbleeds are associated with cerebral amyloid angiopathy)
Brain atrophy
whole brain (should be adjusted for intracranial volume, ICV)regional (hippocampus, specific gyri, lobes. should be adjusted for whole brain volume)cortical or subcorticalsuperficial or deep (sulcal or ventricular enlargement; ditto adjustment) 	If scans are not suited for volumetric techniques or if such techniques are not available, qualitative rating scales may provide an alternative105,106	(semi-) automated quantitative methods preferred but visual checking and manual editing is commonly needed to avoid including the orbits and excluding the brain stem from the whole brain volume68,84,107(sub-)regional brain volume computational methods are in development but their reliability, especially in diseased populations, has yet to be determined77,77,108,108	cross-sectional: brain atrophy can be estimated by comparison with the inner skull volume (an estimate of maximum brain size in youth); all intracranial contents must be included in the ICV measure including veins and meninges which expand to take up space left by a shrinking brain75longitudinal:Serial brain volumes can be measured; a registration-based approach is currently preferred although the field is rapidly advancing109	computational approaches have high reliabilityvisual rating is more varied but can be improved with reference to a standard visual template106subcortical and cortical vascular lesions affect the reliability of automated volumetric techniques,78 particularly in subjects with a high lesion load	consider masking recent small subcortical lesions, lacunes, and PVS when measuring brain volume.77,108 Specific standards are emerging for hippocampal volume measurement110


Table 5: Proposed reporting standards for neuroimaging features of SVD

Aspect	Studies should report on: 
Study sample	demographic details of the research subjects and reference population from which they were drawn
	proportions with vascular risk factors and how measured
	stroke and its subtype(s) as well as other vascular disease
	timing of imaging and clinical assessments in relation to disease presentation (if relevant)
	any clinical or imaging follow-up with time intervals
	for studies on cognition or specific physical functions: details of test versions used, who administered them, their training
	for cognitive studies: assessment of premorbid cognitive ability and of depression
Image acquisition	scanner characteristics (type and manufacturer, field strength, coils, high order shim and use of shimming routines, quality assurance (QA) protocol for scanner and frequency of QA assessment), high order shim and use of shimming routines, quality assurance (QA) protocol for scanner and frequency of QA assessment)
	use of multiple scanners 
	change of scanners or change to a scanner system during study
	MRI sequences, acquisition parameters ( including as appropriate: repetition time, echo time, inversion time, echo train length), acquisition and reconstruction matrices, field-of-view), slice thickness including gaps and scanning plane, details of selected options (tailored excitation pulses, parallel imaging, flow compensation, preparation pulses, etc.), total acquisition time. If a work in progress package is used, as much information as possible should be provided
Image analysis / postprocessing	use and qualification of a central analysis facility, or training procedure across multiple analysis centres
	whether analyses were done blinded to initial presentation or other data (specify) that might bias interpretation
	details of qualitative visual rating and quantitative computational methods including web-address if available for download, or appendix describing the method in detail
	for visual rating scales: whether images were rated centrally by a single or small number of readers; the raters’ background (e.g. neurology, psychiatry, neuroradiology, radiology) and experience; rater reliability (intra and inter-rater)
	for studies using computational image analysis programs: training of the analyst(s), any expert supervision and the background of the expert; repeatability
	statistical methods used in data analysis
	ideally: sample size estimation
SVD-specific aspects	for recent small subcortical infarcts (rSSI): specify whether infarcts are symptomatic or not, location, size, shape, and number; the delay from stroke to imaging, and the proportion with visible acute lesion on DWI and/or FLAIR/T2
	for lacunes of presumed vascular origin: location, size, shape and number; distinguish haemorrhagic lesions from lacunes; for volumetric methods state whether lacunes are counted as part of the CSF volume, as part of the WMH volume or as separate ‘lacune volume’
	for white matter hyperintensities (WMH) of presumed vascular origin: specify if grey matter and brain stem hyperintensities are included (and if so refer to all hyperintensities collectively as ‘; rating scale or volume measurement software used, observer reliability; whether the WMH volume was adjusted for intracranial or brain volume and how this was done; whether lacunes were included into WMH or measured separately, and whether acute lesions were masked
	for perivascular spaces: separate between PVS of the basal ganglia and white matter; describe how qualitative aspects considered (number, location,size etc.) are defined; observer reliability of the rating scale
	for cerebral microbleeds: number and distribution as divided into lobar, deep and infratentorial (brain stem and cerebellum); full details of image acquisition parameters; standardized rating scales applied
	for atrophy: rating scale or method of volume measurement and whether corrected for intracranial volume and if so how



Table 6: Future Challenges in imaging SVD-related changes

Aspect	Questions to be addressed: 
Recent small subcortical infarcts (rSSI)	how can different aetiological subtypes (e.g. embolic, parent or branch artery atheroma, intrinsic SVD), be better differentiated by neuroimaging?
	what proportion of infarcts cavitate, become WMH, or subsequently disappear on conventional MR scans and what are the factors determining conversion in one or the other direction.
Lacunes of presumed vascular origin	how can the methods for distinguishing lacunes from PVS be improved?
	how do secondary degenerative changes in the vicinity of lacunes influence their size and shape over longer time periods?
	how important is the presence of a hyperintense rim for differentiating lacunes from other small cystic structures, e.g. PVS?
White matter hyperintensities (WMH) of presumed vascular origin	to what extent do perivascular and deep WMH differ in terms of mechanisms and clinical consequences? to address this clear definitions and standardized protocols for distinguishing perivascular from deep WMH are needed
	how can newer imaging techniques such as measurements of T1 water content aid in better characterizing WMH and determining their impact on connected brain regions (e.g. cortex) and clinical symptoms?
	Is there pathological or epidemiological justification for distinguishing between hyperintensities in grey matter and those in white matter?
Perivascular spaces (PVS)	what are the mechanisms underlying (multiple) PVS?
	what is the relationship between PVS diameter, risk factors and potential clinical consequences? Can a PVS diameter be identified such that PVS of greater diameter can be considered to be pathologically enlarged?
	how do PVS relate to SVD-related vascular and parenchymal lesions?
	how do PVS relate to brain atrophy and neurodegenerative pathology?
	how can the protocols for detecting and quantifying PVS be improved?
	what are the clinical consequences of PVS?
	what is the clinical utility of rating PVS
Cerebral Microbleeds (CMB)	how do different neurodegenerative or vascular pathologies influence the pathology, spatial distribution and imaging appearance of microbleeds?
	how reliable, sensitive or specific is the distribution of CMB to amyloid angiopathy or hypertension? 
	what is their predictive value with respect to cognitive and functional decline?
	what is their clinical utility with respect to guiding treatment decisions (e.g. use of thrombolysis and antithrombotic therapy)?
	how do different protocols for imaging and quantifying microbleeds compare and how can findings obtained through different protocols be integrated into a common read-out?
Brain atrophy	to what extent do SVD-related vascular lesions affect measures of brain atrophy (cortical, subcortical, gray versus white matter?)
	to what extent does brain atrophy (cortical, subcortical, gray and white matter) impact on volumetric measures of vascular lesions?
	what are the mechanisms underlying secondary brain atrophy mediated by vascular lesions?
	what are the clinical consequences of secondary brain atrophy mediated by vascular lesions?
Other vascular lesions	
       Microinfarcts	what is their frequency in neurodegenerative disease?
	what are their clinical consequences?
	what are the imaging signatures of acute microinfarcts on clinical scanning at 1.5 and 3.0 Tesla?
       Superficial siderosis	what is the frequency in Alzheimer’s disease?
	how frequently does acute sulcal subarachnoid hemorrhage lead to siderosis?
	to what extent do these lesions affect cortical neuronal function?
	what are their clinical consequences, including the frequency of subsequent symptomatic subarachnoid or intracerebral hemorrhage?
General	how can direct imaging of small intracerebral arteries be improved?
	how can subtle changes of vascular origin be differentiated from changes mediated by other pathologies e.g. neurodegeneration and what are the exact histopathological substrates?
	to what extent do SVD-related lesions cause secondary neurodegeneration and what are the underlying mechanisms?
	how do vascular lesions interact with neurodegenerative pathology in causing cognitive decline and other clinical manifestations, in particular, physical disability, gait disturbance, and depression?
	is there any suitable imaging scale that allows integrating multiple SVD-related imaging findings and what is the utility of this scale for research and for clinical practice (e.g. for risk prediction and treatment stratification)?
	how can imaging of vascular manifestations be used to improve the selection of patients included into future clinical trials and in measuring their outcome?
	how can the protocols for measuring BBB integrity be improved and how do SVD-related and neurodegenerative pathology interact in influencing BBB integrity?
	what is the relationship between alterations in cerebral blood flow and volume with ischemic brain pathology?




Figure 1: Variable fates of SVD-related lesions and convergence of aetiologically different acute lesions to result in similar late appearances on MRI: arrows indicate possible late fates of acute MR imaging findings; black arrows indicate common fates of recent small subcortical infarcts; solid grey arrows indicate less common and grey dashed arrows indicate least common late fates, according to best available current knowledge.





Figure 2: Characteristics of SVD-related MR imaging findings: illustrative examples (upper panel) and schematic representation (middle panel) of MR features of different SVD-related changes on typical scans are shown together with a summary of imaging characteristics (lower panel) for individual lesions;  = increased signal; = decreased signal; = isointense signal 
















Figure 3: Secondary brain atrophy in a 55 year old patient with documented SVD. The follow-up scan (T1-weighted image) shows marked sulcal widening (white arrowheads) particularly in occipital brain regions as well as ventricular enlargement (black arrowheads) in the absence of new infarctions during follow-up. The FLAIR image (left panel) shows marked WMH.
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